Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...
Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump.
With speculation online about OpenAI having reached the AGI stage of ChatGPT development, Sam Altman says that's not what's ...
OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI ...
WIth one foot out the White House door, the Biden administration issued 2 documents Musk is now using in his battle to break ...